Financials
- Fiscal year
- 2024
- Total assets
- €63,724
- Loss
- -€3,253
- Solvency
- 60.6%
Turnover▼ 18.7%
Net result
20192023
S.C. Pharma
ActiveSummary
S.C. Pharma has been active since 2018 and the Belgian State Gazette contains no insolvency or warning signals. The 2024 annual accounts show equity of €38,607 and a net result of -€3,253. Equity is growing by ~6.1% per year across the filed fiscal years. The computed 12-month bankruptcy probability is 1.4% (low).
Overview
What they do
Retail sale of pharmaceutical products
NACE 47730
1 site
How big
€63,724total assets 2024
- Equity
- €38,607
- Loss
- -€3,253
Turnover not published (abridged schema)
Who decides
Accounts 44 d early0 of 4 deeds read
Why 62- Higher-failure-rate sector- Annual accounts: weaker financial profile- Higher-failure-rate region- Limited track recordLatest accounts filed on timeShow the evidence
Checked score
Score 2024
Axes · tick = 2023
Profitability62▼-27
Solvency86▲+6
Growth35=
Track record100
Bankruptcy probability, 12 months
1.4%
Low
0%0.5%1.5%4%10%≥ 25%
Credit up to €2,000 at 30 days acceptable
Liquidity short (current ratio 0.43 against 0.23 in 2023; short-term debt: 39.4% and cash: 4.6% of total assets), and 39.4% of the assets are financed with debt.
Credit check for your own amount and term
Show the recommended maximum : and see how the verdict changes with amount, term and advance.
Signals
Five signals. The signal on the left, the evidence on the right.
+raises risk○neutral
raises risk · Higher-failure-rate sector
In this sector companies fail more often than the Belgian average.
Gazette · bankruptcies per sector, NACE 47
Relative position
BE, all sectors
reference
Retail trade (NACE 47)
about 45% more bankruptcies
← fewer bankruptcies
more bankruptcies →
raises risk · Annual accounts: weaker financial profile
The latest annual accounts show a weaker profile in solvency, result or liquidity than companies that stay afloat.
NBB · annual accounts 2024Solvency, return and age of the figures
Solvency
60.6%
Return on assets
-5.1%
Age of the figures
21 mo
raises risk · Limited track record
This company has not been active as long as an established one and statistically fails somewhat more often.
KBO · incorporation dateAge against the risk zone
neutral · Latest accounts filed on time
The financial year that closed on 31-12-2025 was due by 31-07-2026 and was filed on 17-06-2026, 44 days ahead of the deadline.
NBB · 7 filingsDeviation from the deadline
2025
44 d early
2024
35 d early
2023
35 d early
2022
33 d early
2021
53 d early
2020
25 d early
2019
51 d early
← before the deadline
after the deadline →
tick = median of all Belgian filingsring = median in the sector
This company filed its last 7 accounts on average 39 days before the deadline; the sector median for financial year 2024 is on the deadline day, and 47% of the sector filed late.
Checked, nothing found (2)
neutral · The next deadline is still running
The next financial year closes on 31-12-2026 and is due by 31-07-2027. Nothing is late today. Usually files around 26 June (5 of the last 5 filed years within 30 days of that day).
Companies Code · seven monthsPosition in the running window
02-10-2026 today31-12-2026 close31-07-2027 deadline
- Annual accounts filedfiscal year 2025 · micro…
- Annual accounts filedfiscal year 2024 · micro…
- Weakest financial yearnet -€3,253
Key points
By topic
Timeline
- Events
- 9
- Since
- 2020
- Next accounts
- by 31-07-2027
- 17-06-2026Annual accounts filed
- 26-06-2025Annual accounts filed
- 31-12-2024Weakest financial year
Company details
- Sites
- 1
- Legal form
- Private limited company
- Activity
- Retail sale of pharmaceutical productsNACE 47730
- Founded
- 17-08-2018
- Year ends
- 31-12
- Peppol
- Reachable for e-invoices
Go further with this company
How much credit can you give this customer, and on what term?Credit check What should you check before you do business with this company?Supplier due diligence Can you accept this company as a client under the anti-money-laundering law?AML client file Which of your other customers can you e-invoice via Peppol?Peppol check How does this company compare with its sector?Sector benchmark What changed in the latest annual accounts?What changed
Your own company? See how customers, suppliers and banks see it and what to improve first.
Investigating this company? Keep it with today's facts in a case file.